Floatz logo

TIPELUKAST

IPF

MediciNovaSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the IPF cohort.

Asset / SponsorPhaseRating
hsk44459
Haisco Pharmaceutical Group Co., Ltd.
Phase 3BB
rxc007
Redx Pharma Ltd
Phase 2B
Tazarotene
GRI Bio Operations, Inc.
Phase 2B
sb17170
SPARK Biopharma
Phase 2CCC
Rvt-1601
Respivant Sciences GmbH
Phase 2CCC

View all 9 →

Same molecule, other indications

TIPELUKAST is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
57 / 100
View asset →
hypertriglyceridemiaDormant
B
Indicative ·
57 / 100
View asset →
HypercholesterolemiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →